JAG1 and colorectal carcinoma: In addition, treatment with OXA and 5-FU promotes robust Jag1-ICD processing through ERK1/2 activation, resulting in the upregulation of Jag1-ICD-dependent pro-survival targets and conferring resistance to apoptosis in KRASmut CRC cells [22].